

COSTEM 2021 –Scientific Program

All timing in CET

Thursday, October 21	
14:00-14:30	Place of allogeneic stem cell transplantation in multiple myeloma <i>Meet the Expert (MTE) Session</i>
14:30-15:00	TBA <i>Meet the Expert (MTE) Session</i>
15:00-15:30	Break
15:30-17:00	New chapters in the treatment of NHL and MM patients: CAR T <i>Industry Symposium</i>

Friday, October 22			
	Hall A		
09:00-10:45	Session 1: Opening Session		
09:00-09:15	Welcome Note Nicolaus Kröger, Germany; Arnon Nagler, Israel		
09:15-09:45	Controversy: Are CAR T cells the standard treatment for refractory DLBCL?		
09:15-09:30	Yes: Stephen Schuster, USA		
09:30-09:45	No: Mehdi Hamadani, USA		
09:45-10:15	Controversy: Is there a need for allogeneic SCT consolidation in ALL patients post CAR?		
09:45-10:00	Yes: Peihua Lu, China		
10:00-10:15	No: Michael Pulsipher, USA		
10:15-10:45	Panel discussion of both controversies Moderators: Nicolaus Kröger, Germany; Arnon Nagler, Israel		
10:45-11:00	Break		
	Hall A		Hall B
11:00-12:30	Session 2: Multiple myeloma I		11:00-12:30
11:00-11:30	Controversy: Are CARs better for R/R Myeloma than antibodies?		11:00-11:30
11:00-11:15	Yes: Noopur Raje, USA		11:00-11:15
11:15-11:30	No: Hermann Einsele, Germany		11:15-11:30
			Session 3: Acute myeloid leukemia
			Controversy: Maintenance post Allo in FLT3+ AML: Is sorafenib the new standard?
			Yes: Andreas Burchert, Germany
			No: Yi-Bin Chen, USA

11:30-12:00	Controversy: Still a role of allogeneic SCT as salvage treatment in MM? 11:30-11:45 Yes: Gösta Gahrton , Sweden 11:45-12:00 No: Philippe Moreau , France	11:30-12:00	Controversy: Is RIC sufficient in MRD neg. AML patients? 11:30-11:45 Yes: Andreas Bacigalupo , Italy 11:45-12:00 No: Charles Craddock , UK
12:00-12:30	Panel discussion of both controversies Moderators: Nicolaus Kröger , Germany; Hermann Einsele , Germany	12:00-12:30	Panel discussion of both controversies Moderators: Charles Craddock , UK; Arnon Nagler , Israel
12:30-13:00	<i>Break – Visit Exhibition</i>		
13:00-14:15	Paving the way to transplant in Acute Leukemias <i>Industry Symposium</i>		
14:15-14:30	<i>Break</i>		
	Hall A		Hall B
14:30-16:00	Session 4: Haploidentical transplant	14:30-16:00	Session 5: Severe aplastic anemia and HLA-identical sibling SCT
14:30-15:00	Controversy: Is PTCy the better Haplo approach than ATG? 14:30-14:45 Yes: Leonido Luznik , USA 14:45-15:00 No: He Huang , China	14:30-15:15	Controversy: Does introduction of eltrombopag change transplant indication for sAA? Moderator: Carlo Dufour , Italy 14:30-14:45 Yes: Antonio Risitano , Italy 14:45-15:00 No: Regis Peffault de Latour , France 15:00-15:15 Discussion
15:00-15:00	Controversy: Is GVL stronger in Haplo than in MUD for AML? 15:00-15:15 Yes: Nicolaus Kröger , Germany 15:15-15:30 No: Arnon Nagler , Israel	15:15-16:00	Controversy: Do we need ATG/ATLG for GVHD prophylaxis in HLA-identical sibling transplant? Moderator: Francesca Bonifazi , Italy 15:15-15:30 Yes: He Huang , China 15:30-15:45 No: Robert Soiffer , USA 15:45-16:00 Discussion
15:30-16:00	Panel discussion of both controversies Moderator: Didier Blaise , France		
16:00-16:15	<i>Break</i>		
	Hall A		Hall B
16:15-17:45	Session 6: GVHD I	16:15-17:45	Session 7: Acute lymphocytic leukemia
16:15-16:45	Controversy: Is Ruxolitinib the new standard for second line therapy for cGVHD? 16:15-16:30 Yes: Hildegard Greinix , Austria 16:30-16:45 No: Steven Pavletic , USA	16:15-16:45	Controversy: How to bridge relapsed ALL to transplant? 16:15-16:30 Blinatumomab: Renato Bassan , Italy 16:30-16:45 Inotuzumab: Matthias Stelljes , Germany
16:45-17:15	Controversy: Should we perform gut decontamination pre-transplant? 16:45-17:00 Yes: Ernst Holler , Germany	16:45-17:15	Controversy: Can allogeneic SCT in Ph+ ALL be avoided? 16:45-17:00 Yes: Robin Foa , Italy 17:00-17:15 No: Alessandro Rambaldi , Italy

17:00-17:15	No: Marcel van den Brink , USA		
17:15-17:45	Panel discussion of both controversies Moderators: Daniel Wolff , Germany; Steven Pavletic , USA	17:15-17:45	Panel discussion of both controversies Moderators: Dieter Hoelzer , Germany; Matthias Stelljes , Germany

Saturday, October 23			
	Hall A		Hall B
09:30-11:00	Session 8: Myelodysplastic syndrome	09:30-11:00	Session 9: GVHD II
09:30-10:15	Controversy: Does mutation screening impact transplant decisions in MDS in 2020? Moderator: Ibrahim Yakoub-Agha , France	09:30-10:00	Controversy: Is PTCy the better GvHD prophylaxis than ATG in MUD?
09:30-09:45	Yes: Marie Robin , France	09:30-09:45	Yes: Mohamad Mohty , France
09:45-10:00	No: Avichai Shimoni , Israel	09:45-10:00	No: Francesca Bonifazi , Italy
10:00-10:15	Discussion		
10:15-11:00	Controversy: Should novel agents be used for induction prior to transplant in MDS EB1/2? Moderator: Avichai Shimoni , Israel	10:00-10:30	Controversy: Is Haplo the alternative to MUD in AA?
10:15-10:30	Yes: Uwe Platzbecker , Germany	10:00-10:15	Yes: Mahmoud Aljurf , Saudi Arabia
10:30-10:45	No: Ibrahim Yakoub-Agha , France	10:15-10:30	No: Carlo Dufour , Italy
10:45-11:00	Discussion	10:30-11:00	Panel discussion of both controversies Moderators: Andreas Bacigalupo , Italy; Regis Peffault de Latour , France
11:00-11:15	<i>Break</i>		
	Hall A		Hall B
11:15-12:45	Session 10: Myelofibrosis	11:15-12:45	Session 11: Multiple myeloma II
11:15-11:45	Controversy: 60y DIPSS intermediate I with <i>ASXL1</i> , <i>EZH2</i> , <i>SRSF2</i> Allo	11:15-11:45	Controversy: Is there a role for Auto in Amyloidosis in 2021?
11:15-11:30	Pro: Nicolaus Kröger , Germany	11:15-11:30	Yes: Stefan Schönland , Germany
11:30-11:45	Con: Francesco Passamonti , Italy	11:30-11:45	No: Giampaolo Merlini , Italy
11:45-12:15	Controversy: Early Allo in PMF patient responding to JAK2 inhibitor	11:45-12:15	Controversy: Is double Auto upfront in high-risk MM standard?
11:45-12:00	Pro: Juan Carlos Hernandez-Boluda , Spain	11:45-12:00	Yes: Pieter Sonneveld , Netherlands
12:00-12:15	Con: Donal McLornan , UK	12:00-12:15	No: Sergio Giral , USA
12:15-12:45	Panel discussion of both controversies Moderators: Marie Robin , France; Francesco Passamonti , Italy	12:15-12:45	Panel discussion of both controversies Moderators: Pieter Sonneveld , Netherlands; Hartmut Goldschmidt , Germany

12:45-13:15	<i>Break - Visit Exhibition</i>		
13:15-14:30	<i>TBA</i> <i>Industry Symposium</i>		
14:30-14:45	<i>Break</i>		
	Hall A		Hall B
14:45-16:15	Session 12: Paediatrics	14:45-16:15	Session 13: Lymphoma
14:45-15:15	Controversy: Is TBI needed for allograft in ALL?	14:45-15:15	Controversy: Are monoclonal antibodies as effective as CAR-T in R/R DLBCL?
14:45-15:00	Yes: Christina Peters , Austria	14:45-15:00	Yes: Marion Subklewe , Germany
15:00-15:15	No: Rupert Handgretinger , Germany	15:00-15:15	No: Francis Ayuk , Germany
15:15-15:45	Controversy: Is haplo the alternative donor of choice for sickle cell anemia?	15:15-15:45	Controversy: Do CAR-T-cells have a role in treatment of CLL?
15:15-15:30	Yes: Selim Corbacioglu , Germany	15:15-15:30	Yes: David Porter , USA
15:30-15:45	No: Josu de la Fuente , UK	15:30-15:45	No: Ohad Benjamini , Israel
15:45-16:15	Panel discussion of both controversies Moderators: Selim Corbacioglu , Germany; Christina Peters , Austria	15:45-16:15	Panel discussion of both controversies Moderators: David Porter , USA; Robin Foa , Italy
16:15-16:30	<i>Break</i>		
	Hall A		Hall B
16:30-18:00	Session 14: COVID (I) and VOD	16:30-18:00	Session 15: Hodgkin lymphoma
16:30-17:15	Controversy: Are patients after resolution of COVID-19 at higher risk after allogeneic SCT?	16:30-17:00	Controversy: Is there a role for Allo in HL?
16:30-16:45	Moderator: Alessandro Rambaldi , Italy	16:30-16:45	Yes: Anna Sureda , Spain
16:45-17:00	Yes: Per Ljungman , Sweden	16:45-17:00	No: Andreas Engert , Germany
16:45-17:00	No: Malgorzata Mikulska , Italy		
17:00-17:15	Discussion		
17:15-18:00	Controversy: Do we need new diagnostic criteria for VOD?	17:00-17:30	Controversy: Is Haplo the donor of choice in relapsing HL for allogeneic SCT?
17:15-17:30	Moderator: Antonio Pagliuca , UK	17:00-17:15	Yes: Didier Blaise , France
17:30-17:45	Yes: Selim Corbacioglu , Germany	17:15-17:30	No: Norbert Schmitz , Germany
17:30-17:45	No: Rafael Duarte , Spain	17:30-18:00	Panel discussion of both controversies
17:45-18:00	Discussion		Moderators: Norbert Schmitz , Germany; Michael Bishop , USA
18:00-18:15	<i>Break</i>		
18:15-19:15	<i>COSTEM Virtual Poster Walk and Awards</i>		

Sunday, October 24

09:30-11:00	Session 16: Cellular therapies I
09:30-10:00	Controversy: Are dual CARs more effective? 09:30-09:45 Yes: Nirali Shah , USA 09:45-10:00 No: Michael Bishop , USA
10:00-10:30	Controversy: Are NK-CAR cells as effective as CAR-T-cells? 10:00-10:15 Yes: Ulrike Köhl , Germany 10:15-10:30 No: Michael Hudecek , Germany
10:30-11:00	Panel discussion of both controversies Moderators: Michael Hudecek , Germany; Chiara Bonini , Italy
11:00-11:15	<i>Break</i>
11:15-12:45	Session 17: Cellular therapies II and COVID (II)
11:15-12:00	Controversy: Are TCR engineering-based cell therapies the next buster in T-cell based immunotherapy? Moderator: Michael Bishop , USA 11:15-11:30 Yes: Chiara Bonini , Italy 11:30-11:45 No: Christian Chabannon , France 11:45-12:00 Discussion
12:00-12:45	Controversy: Is early COVID vaccination after allogeneic stem cell transplantation effective? Moderator: Per Ljungman , Sweden 12:00-12:15 Yes: Rafael de la Cámara , Spain 12:15-12:30 No: Malgorzata Mikulska , Italy 12:30-12:45 Discussion
12:45-13:00	Closing Remarks Nicolaus Kröger , Germany; Arnon Nagler , Israel